Last reviewed · How we verify
Carbon-14 radio-labeled SRT2104
Carbon-14 radio-labeled SRT2104 is a Small molecule drug developed by Sirtris, a GSK Company. It is currently in Phase 1 development.
At a glance
| Generic name | Carbon-14 radio-labeled SRT2104 |
|---|---|
| Sponsor | Sirtris, a GSK Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carbon-14 radio-labeled SRT2104 CI brief — competitive landscape report
- Carbon-14 radio-labeled SRT2104 updates RSS · CI watch RSS
- Sirtris, a GSK Company portfolio CI
Frequently asked questions about Carbon-14 radio-labeled SRT2104
What is Carbon-14 radio-labeled SRT2104?
Carbon-14 radio-labeled SRT2104 is a Small molecule drug developed by Sirtris, a GSK Company.
Who makes Carbon-14 radio-labeled SRT2104?
Carbon-14 radio-labeled SRT2104 is developed by Sirtris, a GSK Company (see full Sirtris, a GSK Company pipeline at /company/sirtris-a-gsk-company).
What development phase is Carbon-14 radio-labeled SRT2104 in?
Carbon-14 radio-labeled SRT2104 is in Phase 1.